Nanjing Leads Biolabs Reports 21.8-Month Median PFS for LBL-034

Updated first-in-human data showed median PFS of 21.8 months at 400–1,200 μg/kg in RRMM, with predominantly low-grade CRS. The company said FDA orphan drug designation and Fast Track were secured, and Phase III preparation is underway.